Loading animation
  • Home
  • About us View About us's child pages
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages
      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • Pain Relief View Pain Relief's child pages
      • TPR100 Clinical Data
      • TPR100 Commercial potential
      • TIB200
    • Products FAQ's View Products FAQ's's child pages
      • MED3000 FAQs
      • FM71
      • CBD100 FAQs
      • DermaSys® FAQs
      • TPR100 FAQs
  • Investor centre View Investor centre's child pages
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages
      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages
      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us

Please use the arrows to navigate to the sub pages

  • About us View About us's child pages

    About us

    Futura Medical is a pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys®  technology.

    Explore this section
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages

    What we do

    Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain.

    Explore this section
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages

      MED3000

      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • Pain Relief View Pain Relief's child pages

      Pain Relief

      • TPR100 Clinical Data
      • TPR100 Commercial potential
      • TIB200
    • Products FAQ's View Products FAQ's's child pages

      Products FAQ's

      • MED3000 FAQs
      • FM71
      • CBD100 FAQs
      • DermaSys® FAQs
      • TPR100 FAQs
  • Investor centre View Investor centre's child pages

    Investor centre

    Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.

    WEBCASTS

    Explore this section
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages

      Videos and webcasts

      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages

      Shareholder centre

      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages

    Media

    This section contains the latest RNS, news and videos.

    Explore this section
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us
  • About us View About us's child pages
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages
      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • Pain Relief View Pain Relief's child pages
      • TPR100 Clinical Data
      • TPR100 Commercial potential
      • TIB200
    • Products FAQ's View Products FAQ's's child pages
      • MED3000 FAQs
      • FM71
      • CBD100 FAQs
      • DermaSys® FAQs
      • TPR100 FAQs
  • Investor centre View Investor centre's child pages
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages
      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages
      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us

    Products FAQ's

    • Home
    • What we do
    • Products FAQ's

    MED3000 FAQs

    • MED3000 FAQs
    • FM71
    • CBD100 FAQs
    • DermaSys® FAQs
    • TPR100 FAQs
    • What is MED3000?

      MED3000, our lead product, is a topical gel which utilises our proprietary technology DermaSys®, developed specifically for the treatment of erectile dysfunction (“ED”). MED3000 is a fast-acting topical treatment which has the potential to be a highly differentiated product by addressing significant unmet needs in the ED market.

    • How does MED3000 work?

      MED3000 is a topical gel applied directly to the head (glans) of the penis for the treatment of ED.

      MED3000 works through an evaporative and unique mode of action.  MED3000’s combination of volatile solvent components creates an evaporative and novel action that stimulates nerve sensors in the highly innervated glans penis rapidly, leading to smooth muscle relaxation, tumescence and erection.

       

    • I have been following the progress of development of this product and wondered if there is any further information regarding a UK release date for sale to the general public?

      Futura aims to create a network of licensing and distribution partners with strength in brand building, pharmaceutical credibility and regional infrastructure and marketing expertise for long-term distribution of MED3000 across the globe. We continue to target initial launches later in 2022, although exact markets have not yet been agreed with distribution partners. Further launches are expected in in 2023.

    • When will MED3000 be on the market in the EU?

      On Friday 30th April the Company announced that it has now received its MDR EU Quality Management Certificate for the placing on the market of a Class II(b) medical device known as MED3000 (“CE mark approval”).

      The approval of MED3000 from the EU Notified Body paves the way for rapid approval in many countries around the world, including in the Middle East, Africa, the Far East Latin American regions which allow “fast-track” review based on recognition of the EU CE mark. Due to post-Brexit arrangements, the EU CE mark can be used to market the product in Great Britain until 30 June 2023 by which time a specific UKCA mark has to be obtained. This will be a streamlined process since it is understood the UK application can bridge to the EU approval.

      Futura has retained specialist corporate advisers to assist the company in the appointment of world-wide distribution partners. Once appointed all marketing and marketing aspects of MED3000 including launch will be handled by them. Futura's breakthrough, topical gel formulation MED3000 will become the first pan-European topical treatment for erectile dysfunction ("ED") available without the need of a doctor's prescription.

      We are currently targeting initial launches in Europe in H1 2023.

    • How can I buy MED3000? Is MED3000 available for purchase?

      MED3000 is currently not available for purchase.

    • When will MED3000 be on the market in the US?

      As previously announced, following a number of meetings with the US Food and Drug Administration (FDA) the FDA agreed that an application may be made for MED3000 as a medical device for ED treatment, with a De Novo classification. A number of pre-submissions meeting with the FDA took place to define and confirm the detail of the work required for OTC classification in the USA for MED3000.

      Data from a confirmatory clinical study, FM71, announced in August 2022, alongside additional data from previously announced FM57, supports the US regulatory submission for MED3000 with an application for OTC designation. The dossier is on track for submission at the end of September 2022.

      US marketing authorisation of MED3000 by the FDA remains on course for Q1 2023.

    • What is the likelihood of needing to complete further trials to get approval in the US?

      We don’t anticipate needing to complete any further trials to obtain FDA granting marketing authorisation 

    • When will MED3000 be on the market in the rest of the world?

      The approval of MED3000 from the EU Notified Body (as announced on Friday 30th April) paves the way for rapid approval in many countries around the world, including in the Middle East, Africa, the Far East Latin American and Australia regions which allow “fast-track” review based on recognition of the EU CE mark. Due to post-Brexit arrangements, the EU CE mark can be used to market the product in Great Britain until 30 June 2023 by which time a specific UKCA mark has to be obtained. This will be a streamlined process since it is understood the UK application can bridge to the EU approval. Depending on the country these approvals are likely to take between 6 and 12 months from the time of submission.

      In 2021 Futura signed three commercial deals:

      March 2021: Co-High Investment Management to commercialise MED3000 in China and South East Asia.

      August 2021:  m8 Pharmaceuticals to commercialise MED3000 in Brazil and Mexico.

      September 2021:  Labatec Pharma to commercialise MED30 00 in the Gulf and Middle East Region.

      In 2022, Futura entered into the following commercial deals:

      March 2022: A. Menarini Korea Limited for the exclusive rights to MED3000 in South Korea.

      May 2022: Cooper Consumer Health to commercialise MED3000 throughout the European Economic Area, United Kingdom and Switzerland.

       

       

    • Will you be supplying samples to shareholders?

      All distribution will be handled by our appointed distribution partners and retailers. MED3000 addresses the significant and specific medical needs of men who suffer from erectile dysfunction and its use, where approved to be a treatment without the need for a doctor’s prescription, will require careful consideration by the patient in terms of self-diagnosis and use according to product label information.

       

    • Can I request a sample of MED3000 / Eroxon™ ?

      EROXON™ is a gel that is a clinically proven treatment for erectile dysfunction and helps give adult men an erection within 10 minutes.  Eroxon™ is also available without the need of a doctor’s prescription.

      Futura has granted Cooper Consumer Health SAS (“Cooper”) exclusive marketing and distribution rights for Eroxon™ throughout the European Economic Area including the United Kingdom and Switzerland.  All product or sales enquiries will be handled directly by Cooper including professional samples that may be available to healthcare practitioners.

      Contact details can be found at www.cooperconsumerhealth.eu/

    • Will MED3000 work if I have had a prostatectomy?

      At this time we have not tested the product in patients who have undergone radical prostatectomy although the product has been shown to be effective in mild, moderate and severe ED of mixed causes.

    • Can I use MED3000 if I have a medical condition?

      If you have a medical condition you may need to speak to a doctor to discuss your condition to see if the product is suitable for you to use. 

      MED3000 will come with a leaflet part of which will cover warning and precautions and recommend users have a check-up with your doctor as soon as possible within the first 6 months of using MED3000 to ensure that any erection problems are not caused by another serious health condition.

    • When MED3000 launches what do you expect will be the shelf life?

      We anticipate an initial shelf life of 2 years, extended to 3 years when the company generate longer term data.

    • How much will the product sell for? Will there be a consistent price globally?

      The final price has yet to determine however market research supports a single dose price in the region of £5.00

    • What if MED3000 is used in combination with PDE5is? Will post-approval studies be necessary?

      We have not conducted studies on MED3000 in combination with PDE5i’s and it is not included on our proposed label. It is likely that a post-approval study will be needed to demonstrate synergy. We do not anticipate any safety issues in combining the two treatments   Regulatory status in other geographies, especially where there are commercialisation agreements in place e.g. China, LatAm, Gulf States

    • What is the FM71 clinical study?

      What is the FM71 clinical study?
    • Why tadalafil rather than another comparator?

      Why tadalafil rather than another comparator?
    • How fast does the control product, tadalafil work?

      How fast does the control product, tadalafil work?
    • What are the results of the FM71 Study?

      What are the results of the FM71 Study?
    • What claims can you now make?

      What claims can you now make?
    • Who are CBDerma Technology Ltd?

      CBDerma Technology is a company that has been established with backers that have experience in plant derived products.  Futura announced a joint venture collaboration with CBDerma Technology Limited in September 2019 to explore the application of Futura’s advanced proprietary transdermal technology, DermaSys® for the delivery of cannabidiol.

    • What are the potential market sizes for cannabidiol either as a cosmetic or a pharmaceutical?

      The cosmetic market is already significant with the UK, we understand, over £300 million. As a topically applied Pharmaceutical the potential is huge but under-explored so far, with currently very little credible scientific research conducted on topical formulations.

    • Why is DermaSys® an ideal product formulation for cannabidiol?

      DermaSys® provides rapid and targeted local delivery of active pharmaceutical ingredients (API) at therapeutic levels and Generally Recognized As Safe (GRAS) pharmaceutical excipients onto and through the skin to the required site of action with a high level of safety. It is a versatile and bespoke technology that can be tailored to suit the specific active compound being used and the therapeutic indication. Each product is formulated to maximise its benefits for patients and consumers and can be developed for the prescription and consumer healthcare markets as appropriate.

    • What formulation of DermaSys® is used for the CBD100 product? How does this differ from MED3000?

      Our transdermal technology DermaSys® is tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action offering improvements over existing products creating novel indications with compelling commercial potential. This means that our products are highly differentiated in their markets whilst avoiding the risks normally associated with the development of new molecules.

      CBD100 comprises a unique combination of penetration enhancers components and a diffusion enhancer.  It is designed to provide highly efficient penetration of cannabidiol into and through the skin with a stability expected to ensure potency is retained during shelf-life.

    • What is the IP position of this specific formulation?

      A patent application was filed in the UK in August 2020.

    • When will you hear back about the CBD100 patent application?

      We would expect to receive an initial search report on the ‘patentability’ of such application within six months.  This will provide details of other patents or application already in existence which may affect the novelty and inventiveness of any new application.  This may result in some amendment to the patent application ahead of a PCT application next July.

    • What will be the next steps with CBD100?

      We are aiming for CBD100 to be highly differentiated from existing, largely un-regulated, low-tech products in the fast growing cannabidiol market on the basis of quality, stability and efficient delivery to the skin for a number of applications and indications expected to range from cosmeceutical through to pharmaceutical dermal and pain relief treatments. We have now started to explore commercialisation options for CBD100 with CBDerma as stability work continues in parallel.  These options will also be influenced by the regulatory landscape around Cannabis which continues to evolve in the EU and USA.

    • Can I request a sample of CBD100?

      Unfortunately, under the current regulations, Futura Medical are not able to provide samples.

    • What is DermaSys®?

      Futura’s unique transdermal technology DermaSys® enables targeted and rapid delivery of clinically proven effective medical treatments through the skin. 

      Our transdermal technology DermaSys® is tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action offering improvements over existing products creating novel indications with compelling commercial potential. This means that our products are highly differentiated in their markets while avoiding the risks normally associated with the development of new molecules.

      DermaSys® is a versatile normally clear, odourless gel uniquely formulated using  permeation and penetration enhancer components  tailored for each product, to suit the specific therapeutic indication and desired speed of onset and duration of action. Each product is formulated to maximise its benefits for patients and consumers.

    • What is the full IP position of DermaSys® Technology and all its formulations?

      DermaSys® is a proprietary transdermal technology platform with very strong IP offering a high level of product differentiation compared to existing marketed treatments. Each new unique formulation offers the opportunity for additional patent applications and potential patent protection.

    • When do you expect Thornton & Ross to obtain regulatory approval within the UK?

      In February 2019, the UK Medicines and Healthcare products Regulatory Agency (MHRA) responded to Thornton & Ross’s marketing authorisation application filed in July 2018, raising a number of questions requiring additional laboratory work specifically around the permeation characteristics of TPR100 to be conducted. The additional lab work has been completed indicating that absorption of TPR100 is significantly superior to the market leader. These results were discussed with MHRA in a Scientific Advice meeting and it was determined that as there was non-equivalency a clinical study was required. MHRA suggested that the clinical study could be used to support superiority claims for the formulation. Futura are determining how this study could be funded and used to support the product in markets around the world including the US where Voltaren (GSK) has recently achieved OTC designation.

       

    • What formulation of DermaSys® is used for the TPR100 product? How does this differ from MED3000?

      Our transdermal technology DermaSys® is tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action offering improvements over existing products creating novel indications with compelling commercial potential. This means that our products are highly differentiated in their markets whilst avoiding the risks normally associated with the development of new molecules.

      The rapid skin permeation rate offered by our transdermal delivery system, DermaSys®, is ideally suited for targeted topical pain relief. Rapid, targeted and effective skin permeation offers potential benefits in pain management including: improved onset of action, duration and degree of pain relief.

      TPR100 does not require a combination of volatile solvent components to stimulate nerve sensors.  It is designed to provide a sustained mode of action suitable for the treatment of pain and is formulated with this objective in mind.

    • What is the IP position of this specific formulation?

      TPR100's current patent protection runs until February 2028 in the USA and Europe.

    Futura Medical logo

    ©2023 Futura Medical

    • Sitemap
    • Contact us
    • Accessibility
    • Terms of use
    • Privacy & cookies policies

    Designed and developed by
    jonesandpalmer.co.uk